AVIR Stock Summary and Trading Ideas (Atea Pharmaceuticals | NASDAQ:AVIR)

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Atea Pharmaceuticals trades on the NASDAQ stock market under the symbol AVIR.

As of August 18, 2026, AVIR stock price climbed to $5.28 with 131,735 million shares trading.

AVIR has a beta of 0.65, meaning it tends to be less sensitive to market movements. AVIR has a correlation of 0.02 to the broad based SPY ETF.

AVIR has a market cap of $423.48 million. This is considered a Small Cap stock.

In the last 3 years, AVIR traded as high as $6.45 and as low as $2.46.

The top ETF exchange traded funds that AVIR belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

AVIR has outperformed the market in the last year with a price return of +50.9% while the SPY ETF gained +20.4%. AVIR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +28.8% and +14.5%, respectively, while the SPY returned +4.1% and +1.3%, respectively.

AVIR support price is $5.04 and resistance is $5.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVIR shares will trade within this expected range on the day.